Synopsis: Posting a 35.6 percent year-on-year jump in Q4 profit on the back of a domestic brand relaunch and a sharp export surge, Sanofi Consumer Healthcare India has delivered its first truly clean quarter in over a year, and the composition of that growth is what demands attention.
A leading consumer healthcare company is firing on all cylinders, with a strong Q4 showing profit and revenue both posting sharp year-on-year jumps. A fully restored product portfolio and a standout export surge are driving the momentum, and investors are taking notice.
With a market capitalization of Rs. 11,074 crore, the shares of Sanofi Consumer Healthcare India Limited were trading at Rs. 4,920.29 per share, up by 5 percent from their previous closing price of Rs. 4,685.74 apiece. It is trading at a P/E of 43.8x.
Q4 FY26 Financial Results
Sanofi Consumer Healthcare India has had a lot riding on its product relaunch cycle, and the quarter ended March 31, 2026, suggests it’s paying off. Revenue from operations jumped 32.8% year-on-year to ₹229.2 crore from ₹172.6 crore.
The backdrop matters here: Combiflam Suspension, Allegra Suspension, and Depura Kids were all voluntarily pulled from shelves in 2024 and gradually brought back through mid-2025, which means this is the first quarter where all three were fully in play. Bottom line profit after tax rose 35.6% to ₹67.8 crore from ₹50 crore, with expenses growing slower than revenues, a sign that scale is beginning to work in the company’s favor. EPS came in at ₹29.44 versus ₹21.69 a year ago.
Zoom out to the full year ending December 31, 2025, and the picture holds up well. Revenue from operations reached ₹878.4 crore, total income came in at ₹896.8 crore, and the company closed 2025 with a net profit of ₹240.1 crore and full-year EPS of ₹104.27, a solid base to build on heading into the new fiscal year.
The Export Surge That Changes the Story
The number that the street will sit with is the 144.4 percent growth in export sales during Q4, recorded on a low base from the year-ago period. Domestic sales grew 15.5 percent for the same quarter. Together, they pushed product sales to Rs. 206.3 crore in Q4, from Rs. 158.6 crore a year earlier.
But the export surge is not an isolated anomaly. Combined with the sequential relaunch of three key domestic brands, Combiflam Suspension (relaunched in June 2025), Allegra Suspension, and Depura Kids (both back on shelves by September 2025), the company now has a fuller portfolio in play for the first time since 2024. Those products had been voluntarily recalled as a precautionary measure in 2024 and were absent entirely in Q4 FY25, making year-on-year comparisons previously skewed.
With those headwinds cleared, the current quarter represents a genuinely clean base. The portfolio is intact, domestic recovery is underway, and export momentum has arrived at a point when it can actually be measured against a normalized domestic business. For investors, that combination of export traction and a full domestic lineup creates better earnings visibility than any single-quarter beat could on its own.
Verdict:
With a fully restored domestic portfolio and export momentum building, the company appears to have turned a corner. The hard work of the relaunch cycle is now behind it, and the numbers are beginning to reflect that. Whether this quarter marks the start of a sustained re-rating or a one-time catch-up remains the key question, but the foundation, for the first time in over a year, looks genuinely solid.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
The post Sanofi Consumer Healthcare Reports 144% Export Surge in this Qtr; What Drove the Growth? appeared first on Trade Brains.